Objective To investigate the effect of nimodipine combined with edaravone in the treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH).
Methods A total of 80 patients with CVS after SAH were randomly divided into observation group and control group, with 40 cases in each group. Both groups were given routine treatment, the control group was treated with edaravone by intravenous drip, while the observation group was treated with edaravone combined with nimodipine by intravenous drip. The total effective rate, levels of inflammatory factors, serum S100β protein, endothelin-1 (ET-1), blood flow velocity of middle cerebral artery (MCA), Glasgow coma score (GCS), National Institutes of Health Stroke Scale (NIHSS), Barthel index (BI) before and after treatment and adverse reactions were compared between the two groups.
Results The total effective rate of the observation group was 97.50%, which was significantly higher than 85.00% of the control group (P < 0.05). After treatment, the levels of inflammatory factors, serum S100β protein, ET-1 and MCA blood flow velocity of the observation group were significantly lower than those of the control group (P < 0.05). After treatment, the GCS score and BI of the observation group were significantly higher than those of the control group, and the NIHSS score was significantly lower than that of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Conclusion The combination of nimodipine and edaravone is effective in the treatment of CVS after SAH, which can effectively inhibit inflammatory response and reduce the severity of CVS.
DownLoad: